Across TCGA pan-cancer cohorts, PHOX2A Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PHOX2A data layer compared with 24 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PHOX2A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PHOX2A expression acts as an unfavorable survival marker.
UCEC and LUSC are the cancer types where PHOX2A Mutation most reproducibly stratifies survival.